Shaoxing Second Hospital
13
4
5
3
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
0.0%
0 terminated/withdrawn out of 13 trials
100.0%
+13.5% vs industry average
46%
6 trials in Phase 3/4
0%
0 of 3 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (13)
Exploratory Study of Venetoclax, Homoharringtonine, Azacitidine Plus G-CSF for Newly Diagnosed AML (VHAG)
Role: collaborator
Prevention of Delayed CINV After Autologous Transplant: Olanzapine-Containing Regimen vs. Dexamethasone-Containing Regimen
Role: collaborator
Ixazomib Plus Low-dose Lenalidomide Versus Ixazomib Alone for Maintenance Treatment of High Risk Multiple Myeloma
Role: collaborator
Comparison Study of EAP and Disease-Specific Chemotherapy Regimens in Hematopoietic Stem Cell Mobilization for Lymphoma
Role: collaborator
Borderline of CME/D3 Dissection for Local Advanced Right-sided Colon Cancer
Role: collaborator
Comparison Study of EAP and CG Regimens for Mobilizing Hematopoietic Stem Cells in Multiple Myeloma Patients
Role: collaborator
Improving In-hospital Stroke Service Utilisation in China
Role: collaborator
An Investigation on the Role of Emergency Departments in Combatting Against COVID-19 in Zhejiang Province
Role: collaborator
Investigation on the Practice Status of Emergency Stuff
Role: collaborator
Treat-to-Target Strategy With Etanercept for Ankylosing Spondylitis
Role: collaborator
Chinese Research Group of Gallbladder Cancer
Role: collaborator
Clinical Study of Pegylated Somatropin to Treat Children Growth Hormone Deficiency
Role: collaborator
Adipose-derived Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome
Role: lead
All 13 trials loaded